Adicet Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $99.1M | $99.3M | $106.0M | $71.2M | $48.9M |
| Operating expenses | $122.1M | $127.6M | $152.0M | $97.5M | $71.2M |
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M |
| Interest expense | $36,000 | $4,000 | $25,000 | $80,000 | $176,000 |
| Pretax income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.1M |
| Income tax expense | $0 | $0 | $0 | $0 | -$125,000 |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M |
| Balance Sheet | |||||
| Cash and equivalents | $38.9M | $56.5M | $159.7M | $257.7M | $277.5M |
| Current assets | $160.9M | $180.1M | $162.3M | $261.0M | $282.4M |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M |
| Current liabilities | $21.5M | $19.4M | $19.3M | $19.7M | $16.3M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M |
| Stockholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M |
| Depreciation and amortization | $6.4M | $6.5M | $6.1M | $2.6M | $1.5M |
| Stock-based compensation | $14.3M | $22.2M | $20.3M | $17.1M | $12.5M |
| Capital expenditure | $1.7M | $1.1M | $4.5M | $16.8M | $13.0M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M |
| Impairments | $0 | $0 | $19.5M | $0 | $0 |
Shares outstanding 9.3M
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.